Prophylaxis Results Set Stage For Expanded Japan Xofluza Use
Shionogi’s novel single-dose flu drug shows promise in first Phase III results in post-exposure prevention, paving the way for a Japanese filing in this setting and potentially expanding already healthy sales.
You may also be interested in...
The coronavirus outbreak shows how vulnerable vast numbers of people remain to potentially deadly viruses. Roche boss Severin Schwan believes that the lessons being learnt about COVID-19 should be applied to tackling flu.
As it waits for a US FDA decision on its antibiotic cefiderocol, the Japanese company has handed over the rights to a Pseudomonas aeruginosa therapy that will go into the clinic next year.
The Swiss group's one-dose drug, seen as a future growth driver, is as effective as its off-patent blockbuster Tamiflu in treating children.